Literature DB >> 16335888

Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling.

Shinji Takai1, Kazuyoshi Kirimura, Denan Jin, Michiko Muramatsu, Katsuhiro Yoshikawa, Yoshiki Mino, Mizuo Miyazaki.   

Abstract

Although the lipophilicities of the various angiotensin II receptor blockers (ARBs) are very different, the relationship between lipophilicity and the protective effect against vascular remodeling is unclear. In this study, we compared the protective effects of a highly lipophilic ARB, telmisartan, and an ARB with low lipophilicity, losartan, on vascular function and oxidative stress in stroke-prone spontaneously hypertensive rats (SHR-SP). SHR-SP received oral placebo, 1 mg/kg telmisartan, or 10 mg/kg losartan for 2 weeks. The blood pressure (BP) in SHR-SP was significantly higher than that in Wistar-Kyoto (WKY) rats before treatment, and the BP was reduced equally in telmisartan- and losartan-treated SHR-SP compared to placebo-treated SHR-SP. Acetylcholine-induced vasorelaxation in isolated carotid arteries was significantly weaker in SHR-SP than in WKY rats, but in both telmisartan- and losartan-treated SHR-SP, acetylcholine-induced vasorelaxation was significantly higher than in placebo-treated SHR-SP. Moreover, acetylcholine-induced vasorelaxation in telmisartan-treated rats was significantly stronger than in losartan-treated SHR-SP. The expression of the endothelial nitric oxide synthase gene was significantly higher in telmisartan- and losartan-treated rats than in placebo-treated SHR-SP, and was significantly higher in telmisartan-treated rats than in losartan-treated rats. In contrast, the expression of the NAD(P)H oxidase subunit p22phox gene in telmisartan-treated SHR-SP was significantly lower than that in losartan-treated SHR-SP. Immunohistochemistry showed that angiotensin II expression in the aorta was significantly lower in telmisartan-treated SHR-SP than in losartan-treated SHR-SP. In conclusion, a highly lipophilic ARB, telmisartan, may be useful for preventing NAD(P)H oxidase activity, and thereby for conferring vascular protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16335888     DOI: 10.1291/hypres.28.593

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  16 in total

Review 1.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Curr Opin Pharmacol       Date:  2007-02-15       Impact factor: 5.547

2.  Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.

Authors:  Mark A Munger
Journal:  P T       Date:  2011-01

Review 3.  Telmisartan: a review of its use in cardiovascular disease prevention.

Authors:  James E Frampton
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 4.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

5.  Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats.

Authors:  Wei-Wei Zhu; Xue-Ping Liu; Nan Wu; Ting-Ting Zhao; Yong Zhao; Jie Zhang; Jian-Hua Shao
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

6.  Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats.

Authors:  Fumihiro Sugiyama; Naohiko Kobayashi; Mayuko Ishikawa; Sho Onoda; Toshihiko Ishimitsu
Journal:  Clin Exp Nephrol       Date:  2012-12-26       Impact factor: 2.801

7.  Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.

Authors:  Yayoi Nishida; Yasuo Takahashi; Tomohiro Nakayama; Masayoshi Soma; Satoshi Asai
Journal:  Cardiovasc Diabetol       Date:  2011-08-10       Impact factor: 9.951

8.  Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator.

Authors:  Yuki Hamano; Takashi Okude; Osamu Yokosuka; Makoto Ogawa
Journal:  Nephron Extra       Date:  2011-09-22

Review 9.  A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.

Authors:  Philippe Gosse
Journal:  Vasc Health Risk Manag       Date:  2006

10.  Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats.

Authors:  Shinji Takai; Denan Jin; Shizuka Aritomi; Kazumi Niinuma; Mizuo Miyazaki
Journal:  Hypertens Res       Date:  2012-11-29       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.